生物技术全球化

Search documents
科兴集团董事长尹卫东:生物医药行业正呈现四大格局变化
Zhong Guo Jing Ji Wang· 2025-08-29 11:51
Core Insights - The 2025 Supply Chain Ecological Conference hosted by Beijing Kexing Holdings Group focused on innovation and collaboration within the biopharmaceutical industry, emphasizing the need for strategic discussions among 69 supply chain partners [1] - The biopharmaceutical industry is experiencing significant changes driven by the pandemic, technological advancements, geopolitical challenges, and the vast domestic market in China, presenting both challenges and opportunities [1] Group 1 - The pandemic has accelerated the application of biotechnology, creating substantial market demand for health solutions [1] - The integration of biotechnology with AI technology is reshaping health demands and unlocking significant growth opportunities [1] - The U.S.-China geopolitical dynamics are prompting a global strategy adjustment for China's biotechnology sector [1] Group 2 - The "Lai Fu Initiative" proposed by the CEO includes four key points aimed at enhancing collaboration and innovation in the health industry [2] - The initiative encourages global partners to participate in China's health industry development, sharing market opportunities and benefits [2] - It advocates for the establishment of joint R&D platforms to accelerate technological breakthroughs and shorten product innovation cycles [2] Group 3 - The initiative emphasizes the need for a comprehensive industry chain collaboration system, transitioning from simple supply-demand relationships to deep integration across the entire industry chain [2] - It highlights the importance of product quality and safety as core competitive advantages in the biopharmaceutical sector [2] - The initiative calls for continuous improvement in product quality and operational efficiency through resource sharing and process optimization [2]
科兴集团董事长尹卫东:当前生物医药行业有四大变化
Xin Lang Ke Ji· 2025-08-29 08:36
Core Insights - The current changes in the biopharmaceutical industry are driven by four major trends: the pandemic has accelerated the application of biotechnology, creating significant health market demand; the integration of biotechnology with AI is reshaping health needs and unlocking substantial growth opportunities; the US-China rivalry poses challenges that compel China's biotechnological globalization and market adjustments; and China is leveraging its 1.4 billion domestic market to establish a global strategy in biotechnology [1] Group 1 - The biopharmaceutical industry's true path forward is to provide "global solutions" for human health, ensuring the best services and technological products meet new health demands, achieving high-quality standards to gain trust from more countries, and maximizing production at the lowest costs to make healthcare accessible [1] - The "Lai Fu Initiative" proposed by the company includes four key points: breaking down cognitive boundaries and practicing two-way openness; focusing on technological innovation to accelerate breakthroughs; upgrading cooperation dimensions to build a collaborative system across the entire industry chain; and adhering to high-quality standards to reduce costs and achieve win-win outcomes [1] Group 2 - The company advocates for the establishment of joint research and development platforms to promote shared technological achievements, accelerate product innovation cycles, and collectively seize the global biopharmaceutical technology high ground, injecting core momentum into industry development [2]